As health care becomes increasingly digitized, scientists, doctors and researchers have to try and decipher unprecedented amounts of data to adequately personalize care. The excess of information available to these experts often outpaces their ability to consume and analyze it. Amazon‘s cloud unit has been working to close that gap.
Amazon Web Services recently launched general availability for Amazon Omics, which helps researchers store and analyze omic data like sequences of DNA, RNA and proteins. The service provides customers with the underlying infrastructure they need to make sense of large amounts of data so they can spend more time making new scientific discoveries.
AWS generates a substantial piece of Amazon’s revenue, pulling in $20.5 billion in the third quarter. The cloud-computing business has been expanding into health care, and while AWS doesn’t disclose revenue projections for particular services, the global genomic data analysis market size is expected to reach $2.15 billion by 2030, according to a report from Straits Research.
Dr. Taha Kass-Hout, chief medical officer at AWS, said the vast majority of health care data is unstructured in nature, which means that about 97% of it goes unused. Indexing and making sense of this information is a challenge, especially when researchers are collecting omic data from tens of thousands of patients.
Prior to his time at Amazon, Kass-Hout served two terms under President Barack Obama and was the first chief health information officer at the U.S. Food and Drug Administration.
Sequencing one human genome can require anywhere from 80 to 150 gigabytes of storage, Kass-Hout said, and some research projects deal with petabytes and exabytes of genomic information.
“You’re talking about almost nine Harry Potter’s worth if you want to print it on a printer,” Kass-Hout told CNBC. “And that’s just for one human being.”
Amazon Omics helps researchers sort through their data by providing them with three components that they can leverage individually or as a collective. Omics-aware object storage helps researchers store and share raw sequence data; Omics Workflows helps run workflows that process raw sequence data at scale; and Omics Analytics simplifies the output of the sequence processing.
More than a dozen customers and partners tested a beta version of the service and are already using Amazon Omics.
For Jeffrey Pennington, chief research informatics officer at the Children’s Hospital of Philadelphia, it’s already made a noticeable impact.
Pennington works in the department of biomedical and health informatics, which uses data and technology to solve issues in child health. He said the department spent five years expanding the infrastructure to analyze omics data, and now it’s no longer something they need to build or maintain themselves.
“We’re a big pediatric academic medical center, but we’re still not big enough to learn and build everything that is required to make productive use of omic data,” Pennington said. “Our time and energy, our effort, our financial wherewithal is much better spent putting the puzzle together rather than generating those pieces in the first place.”
Amazon Omics also encourages collaboration between large research groups, smaller clinical groups and intelligence and pharmaceutical companies, said Boris Oklander, co-founder and chief technology officer of C2i Genomics.
C2i is a biotechnology company that’s working to use genomic data to develop personalized treatments for cancer. Oklander said the company participated in the beta for Amazon Omics after trying to develop its own data-analysis technology.
He said Amazon Omics has created an ecosystem for collaboration that eliminates the need for researchers to build a complex technology from the ground up.
“We’re just democratizing,” he said. “This type of service is something that allows [us] to unlock the value in the investments that different players in this space are doing.”
Other major tech companies have developed similar tools. Microsoft‘s cloud-computing platform Azure launched Microsoft Genomics in 2018 to help researchers interpret data generated by genomic technologies. Google‘s Cloud Life Sciences technology also allows researchers to process biomedical data at a large scale.
Pennington said the Broad Institute and DNAnexus offer popular genomic data analysis services as well, but said they can be difficult to maintain and can analyze fewer data types than Amazon Omics.
Given the sensitive and deeply personal nature of omic data, Kass-Hout said privacy and patient data protection is “job zero” for AWS. He said AWS uses more than 300 security, compliance and governance services and supports 98 security standards and compliance certifications. In doing so, AWS goes “way beyond” regulatory compliance, Kass-Hout said, and it also provides best-practice resources and encryption tools to its customers.
Customers are also responsible for building secure applications on top of Amazon Omics’ services, which guards AWS from seeing or leveraging the data.
Kass-Hout said that ultimately, Amazon Omics serves as a way to efficiently index information so researchers can focus on making real advances in precision medicine.
“If the last decade was about the digitization the health and life science industry has gone through, I truly believe the next decade is about making sense of this data in ways now [where] we can find new therapeutics, new diagnostics, more targeted therapies,” he said.
Dina Powell McCormick, who was a member of President Donald Trump’s first administration, has resigned from Meta’s board of directors.
Powell McCormick, who previously spent 16 years working at Goldman Sachs, notified Meta of her resignation on Friday, according to a filing with the SEC. The filing did not disclose why McCormick was stepping down from Meta’s board, but said her resignation was effective immediately.
Meta does not plan on replacing her board role, according to a person familiar with the matter who asked not to be named due to confidentiality. Powell McCormick is considering a potential strategic advisory role with Meta, but nothing has been decided, the person said.
Powell McCormick joined Meta’s board in April along with Stripe co-founder and CEO Patrick Collison. Meta CEO Mark Zuckerberg said in a statement at the time that the two executives “bring a lot of experience supporting businesses and entrepreneurs to our board.”
Powell McCormick served as a deputy national security advisor to President Trump during his first stint in office and was also an assistant secretary of state during President George W. Bush’s administration.
She is married to Sen. Dave McCormick, R-Pa, who took office in January.
Powell McCormick is the vice chair, president and head of global client services at BDT & MSD Partners, which formed in 2023 after the merchant bank BDT combined with Michael Dell’s investment firm MSD.
With her departure, Meta now has 14 board members, including UFC CEO Dana White, Broadcom CEO Hock Tan and former Enron executive John Arnold.
Elon Musk‘s 2018 CEO pay package from Tesla, worth some $56 billion when it vested, must be restored, the Delaware Supreme Court ruled Friday.
“We reverse the Court of Chancery’s rescission remedy and award $1 in nominal damages,” the judges wrote in their opinion.
In the decision, the Delaware Supreme Court judges said a lower court’s decision to cancel Musk’s 2018 pay plan was too extreme a remedy and that the lower court did not give Tesla a chance to say what a fair compensation ought to be.
The decision on the appeal in this case, known as Tornetta v. Musk, likely ends the yearslong fight over Musk’s record-setting compensation.
Musk’s net worth is currently estimated at around $679.4 billion, according to the Forbes Real Time Billionaires List.
Dorothy Lund, a professor at Columbia Law School, told CNBC that while the Friday opinion may restore the 2018 pay plan for Musk, it leaves the rest of the lower court’s decision unaddressed and intact.
“The court had previously decided that Musk was a controlling shareholder of Tesla and that the Tesla board and he arranged an unfair pay plan for him,” she said. “None of that was reversed in this decision.”
“We are proud to have participated in the historic verdict below, calling to account the Tesla board and its largest stockholder for their breaches of fiduciary duty,” lawyers representing plaintiff Richard J. Tornetta said in an e-mailed statement.
Tesla did not immediately respond to requests for comment.
The Delaware Supreme Court issued the order per curiam with no single judge taking credit for writing the opinion and no dissent noted.
Read more CNBC tech news
Musk’s 2018 CEO pay package from Tesla, comprised of 12 milestone-based tranches of stock, was unprecedented at the time it was proposed. After it was granted, the pay plan made Musk the wealthiest individual in the world.
Tesla shareholder Tornetta sued Tesla, filing a derivative action in 2018, accusing Musk and the company’s board of a breach of their fiduciary duties.
Delaware’s business-specialized Court of Chancery decided in January 2024 that the pay plan was improperly granted and ordered it to be rescinded.
In her decision, Chancellor Kathaleen McCormick also found that Musk “controlled Tesla,” and that the process leading to the board’s approval of his 2018 pay plan was “deeply flawed.”
Among other things, she found the Tesla board did not disclose all the material information they should have to investors before asking them to vote on and approve the plan.
After the earlier Tornetta ruling, Musk moved Tesla’s site of incorporation out of Delaware, bashed McCormick by name in posts on his social network X, formerly Twitter, where he has tens of millions of followers, and called for other entrepreneurs to reincorporate outside of the state.
Tesla also attempted to “ratify” the 2018 CEO pay plan by holding a second vote with shareholders in 2024.
In November, Tesla shareholders voted to approve an even larger CEO compensation plan for Musk.
The 2025 pay plan consists of 12 tranches of shares to be granted to the CEO if Tesla hits certain milestones over the next decade and is worth about $1 trillion in total. The new plan could also increase Musk’s voting power over the company from around 13% today to around 25%.
Shareholders had also approved a plan to replace Musk’s 2018 CEO pay if the Tornetta decision was upheld on appeal. That plan is now nullified.
As CNBC previously reported, a law firm that currently represents Tesla in this appeal penned a bill to overhaul corporate law in Delaware earlier this year. The bill was passed by the Delaware legislature in March, and if it had applied retroactively, it could have affected the outcome of this case.
Every weekday, the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. Stocks were higher Friday, led by a rebound in Big Tech as the AI trade attempted to regain momentum. Nvidia stock jumped nearly 3% after Bernstein noted it is trading at 25 times forward earnings, landing it in the eleventh percentile of valuation over the past decade. That’s cheap for the AI chip leader. Market strength carried across the semiconductor group, with Broadcom , AMD , and Micron all charging higher. A stock that did not participate in the rally was Nike . Shares of the sneaker and sportswear maker are down 9.5% a day after it reported solid earnings results but disappointing guidance. 2. Jim also highlighted the standout year for Wells Fargo under CEO Charlie Scharf. “Don’t bet against Charlie,” he said after The Wall Street Journal reported late Thursday that the bank climbed to No. 7 in the U.S. M & A league table, compared to No. 14 last year. The bank advised on high-profile deals, including Netflix ‘s bid for Warner Brothers and Union Pacific ‘s bid for Norfolk Southern . Financial stocks have been on a tear this year, prompting us on Friday to trim our position in Capital One and lock in significant gains. On Thursday, we increased the price target for Capital One to $270 from $250 and downgraded our rating to a 2. In addition, we increased Goldman Sachs ‘ price target to $925 from $850 and Wells Fargo’s price target to $96 from $90. 3. Boeing shares climbed 2.6% on Friday after JPMorgan reiterated the stock as a top pick while increasing its price target to $245 from $240, implying a 15% upside from its current price of $213 per share. Analysts argue the aerospace manufacturer’s path to growth is simple: build more planes and deliver them. While cash flow expectations have come down, JPMorgan believes there’s visibility to at least $10 billion by the end of the decade. Jim said he likes Friday’s stock price for a buy. He called Boeing a “long-term idea” given the strength in travel. 4. Stocks covered in Friday’s rapid fire at the end of the video were: FedEx , Conagra Brands , KB Home , Oracle , and CoreWeave . (Jim Cramer’s Charitable Trust is long NVDA, AVGO, WFC, GS, COF, BA. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.